Marksans Pharma Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
MARKSANS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Marksans Pharma reported its Q1 FY26 (quarter ended June 30, 2025) unaudited results, approved by the board on August 12, 2025. On a standalone basis, revenue from operations rose to Rs 3,197.34 million, up about 25.6% from Rs 2,545.27 million in Q1 FY25, while profit after tax jumped to Rs 480.56 million from Rs 320.15 million, a roughly 50% increase. On a consolidated basis, revenue grew modestly to Rs 6,199.89 million from Rs 5,906.18 million, but profit after tax fell sharply to Rs 582.02 million from Rs 890.67 million, hurt by a Rs 37.73 million net foreign exchange loss against a gain last year. Statutory auditor MSKA & Associates issued an unmodified (clean) limited review opinion on both the consolidated and standalone results.
Strong standalone performance signals robust growth in the core Indian business, likely positive for sentiment. However, the sharp consolidated PAT decline despite revenue growth, driven by forex losses, may temper near-term enthusiasm. The clean auditor opinion is a reassurance, but the divergence between standalone and consolidated trends is worth watching.